Novita to Present First-in-Class Fascin Inhibitor NP-G2-044 Phase 2 Results in Patients with Advanced and Metastatic Solid Tumors at 2024 ASCO Annual Meeting
Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China
Novita Pharmaceuticals to Present its Fascin Inhibitor NP-G2-044 Phase 1A Results in Patients with Advanced and Metastatic Solid Tumors at 2021 ASCO Annual Meeting